Cargando…

Mucopolysaccharidoses Differential Diagnosis by Mass Spectrometry-Based Analysis of Urine Free Glycosaminoglycans—A Diagnostic Prediction Model

Impaired glycosaminoglycans (GAGs) catabolism may lead to a cluster of rare metabolic and genetic disorders called mucopolysaccharidoses (MPSs). Each subtype is caused by the deficiency of one of the lysosomal hydrolases normally degrading GAGs. Affected tissues accumulate undegraded GAGs in cell ly...

Descripción completa

Detalles Bibliográficos
Autores principales:	D’Avanzo, Francesca, Zanetti, Alessandra, Dardis, Andrea, Scarpa, Maurizio, Volpi, Nicola, Gatto, Francesco, Tomanin, Rosella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046358/ https://www.ncbi.nlm.nih.gov/pubmed/36979466 http://dx.doi.org/10.3390/biom13030532

Ejemplares similares

Glycosaminoglycan signatures in body fluids of mucopolysaccharidosis type II mouse model under long-term enzyme replacement therapy
por: Maccari, Francesca, et al.
Publicado: (2022)

Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment
por: D’Avanzo, Francesca, et al.
Publicado: (2020)

Mucopolysaccharidosis Type VI, an Updated Overview of the Disease
por: D’Avanzo, Francesca, et al.
Publicado: (2021)

Brain RNA-Seq Profiling of the Mucopolysaccharidosis Type II Mouse Model
por: Salvalaio, Marika, et al.
Publicado: (2017)

Molecular diagnosis of patients affected by mucopolysaccharidosis: a multicenter study
por: Zanetti, Alessandra, et al.
Publicado: (2019)

Analysis of normal levels of free glycosaminoglycans in urine and plasma in adults
por: Bratulic, Sinisa, et al.
Publicado: (2022)

Establishment of Glycosaminoglycan Assays for Mucopolysaccharidoses
por: Tomatsu, Shunji, et al.
Publicado: (2014)

Glycosaminoglycans as Biomarkers for Mucopolysaccharidoses and Other Disorders
por: Amendum, Paige C., et al.
Publicado: (2021)

A glycomic workflow for LC–MS/MS analysis of urine glycosaminoglycan biomarkers in mucopolysaccharidoses
por: Nilsson, Jonas, et al.
Publicado: (2023)

Biochemical and molecular analysis in mucopolysaccharidoses: what a paediatrician must know
por: Filocamo, Mirella, et al.
Publicado: (2018)

Circadian transcriptome analysis in human fibroblasts from Hunter syndrome and impact of iduronate-2-sulfatase treatment
por: Mazzoccoli, Gianluigi, et al.
Publicado: (2013)

A modified liquid chromatography/tandem mass spectrometry method for predominant disaccharide units of urinary glycosaminoglycans in patients with mucopolysaccharidoses
por: Chuang, Chih-Kuang, et al.
Publicado: (2014)

Cardiac involvement in MPS patients: incidence and response to therapy in an Italian multicentre study
por: Sestito, Simona, et al.
Publicado: (2022)

The relationships between urinary glycosaminoglycan levels and phenotypes of mucopolysaccharidoses
por: Lin, Hsiang‐Yu, et al.
Publicado: (2018)

Diagnosis of Mucopolysaccharidoses and Mucolipidosis by Assaying Multiplex Enzymes and Glycosaminoglycans
por: Arunkumar, Nivethitha, et al.
Publicado: (2021)

Mucopolysaccharidoses: Cellular Consequences of Glycosaminoglycans Accumulation and Potential Targets
por: Leal, Andrés Felipe, et al.
Publicado: (2022)

Clinical efficacy of Enzyme Replacement Therapy in paediatric Hunter patients, an independent study of 3.5 years
por: Tomanin, Rosella, et al.
Publicado: (2014)

Plasma and Urine Free Glycosaminoglycans as Monitoring Biomarkers in Nonmetastatic Renal Cell Carcinoma—A Prospective Cohort Study
por: Gatto, Francesco, et al.
Publicado: (2022)

Newborn screening for mucopolysaccharidoses: Measurement of glycosaminoglycans by LC-MS/MS
por: Stapleton, Molly, et al.
Publicado: (2020)

Plasma and Urine Free Glycosaminoglycans as Monitoring and Predictive Biomarkers in Metastatic Renal Cell Carcinoma: A Prospective Cohort Study
por: Gatto, Francesco, et al.
Publicado: (2023)

A novel CRISPR/Cas9-based iduronate-2-sulfatase (IDS) knockout human neuronal cell line reveals earliest pathological changes
por: Badenetti, Lorenzo, et al.
Publicado: (2023)

An At-Risk Population Screening Program for Mucopolysaccharidoses by Measuring Urinary Glycosaminoglycans in Taiwan
por: Lin, Hsiang-Yu, et al.
Publicado: (2019)

Visual test for detection of pathological glycosaminoglycans excretion in mucopolysaccharidoses. A diagnostic tool in paediatric rheumatology
por: Rua, MJ, et al.
Publicado: (2008)

Glial degeneration with oxidative damage drives neuronal demise in MPSII disease
por: Zalfa, Cristina, et al.
Publicado: (2016)

Targeted Polymeric Nanoparticles for Brain Delivery of High Molecular Weight Molecules in Lysosomal Storage Disorders
por: Salvalaio, Marika, et al.
Publicado: (2016)

The Complexity of Pain Management in Children Affected by Mucopolysaccharidoses
por: Congedi, Sabrina, et al.
Publicado: (2017)

Assessing the impact of the five senses on quality of life in mucopolysaccharidoses
por: Giugliani, Roberto, et al.
Publicado: (2020)

Neonatal Mass Urine Screening Approach for Early Detection of Mucopolysaccharidoses by UPLC-MS/MS
por: Menkovic, Iskren, et al.
Publicado: (2019)

Effects of flavonoids on glycosaminoglycan synthesis: implications for substrate reduction therapy in Sanfilippo disease and other mucopolysaccharidoses
por: Kloska, Anna, et al.
Publicado: (2011)

Assay for Glycosaminoglycans by Tandem Mass Spectrometry and its Applications
por: Tomatsu, Shunji, et al.
Publicado: (2014)

Developments in Mass Spectrometry for Glycosaminoglycan Analysis: A Review
por: Pepi, Lauren E., et al.
Publicado: (2021)

Validation of Liquid Chromatography-Tandem Mass Spectrometry-Based 5-Plex Assay for Mucopolysaccharidoses
por: Oguni, Tsubasa, et al.
Publicado: (2020)

QueryOR: a comprehensive web platform for genetic variant analysis and prioritization
por: Bertoldi, Loris, et al.
Publicado: (2017)

Targeting Brain Disease in MPSII: Preclinical Evaluation of IDS-Loaded PLGA Nanoparticles
por: Rigon, Laura, et al.
Publicado: (2019)

Personalised medicine in paediatrics: individualising treatment in children with rare neurological diseases
por: Scarpa, Maurizio, et al.
Publicado: (2011)

Mucopolysaccharidoses in northern Brazil: Targeted mutation screening and urinary glycosaminoglycan excretion in patients undergoing enzyme replacement therapy
por: Viana, Gustavo M., et al.
Publicado: (2011)

Prognostic Value of Plasma and Urine Glycosaminoglycan Scores in Clear Cell Renal Cell Carcinoma
por: Gatto, Francesco, et al.
Publicado: (2016)

Anesthesiological risks in mucopolysaccharidoses
por: Moretto, Alessandra, et al.
Publicado: (2018)

The Inflammation in the Cytopathology of Patients With Mucopolysaccharidoses- Immunomodulatory Drugs as an Approach to Therapy
por: Wiesinger, Anna-Maria, et al.
Publicado: (2022)

Plasma Glycosaminoglycans as Diagnostic and Prognostic Biomarkers in Surgically Treated Renal Cell Carcinoma
por: Gatto, Francesco, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_dmd1r3ojffuvu09b95um6phs8i